During IDWeek 2024 in the US, novel antimicrobials in the development pipeline that are poised to make a difference were ...

The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.

Galderma has reported positive data from a Phase III clinical trial of RelabotulinumtoxinA for treating frown lines and ...

Madrigal Pharmaceuticals has finished enrolling patients in a trial of Rezdiffra, a drug candidate for compensated NASH ...

Zymeworks has dosed the first subject in a Phase I trial of ZW171 to treat ovarian cancer, non-small cell lung cancer and ...

At IDWeek 2024, Moderna presented interim results from an ongoing Phase I/II dose-ranging trial for mRNA-1403, a vaccine ...

Roche has released positive topline one-year findings from a Phase IV trial of Vabysmo (faricimab) to treat diabetic macular ...

Sepsis is a life-threatening complication arising from an infection, which occurs when the body’s response to the infection ...

Find Therapeutics has dosed the first subject in a Phase I trial of FTX-101 as a potential treatment for chronic optic ...

Nurix Therapeutics has reported positive clinical data from its ongoing Phase Ia/Ib trial of NX-5948 for Waldenstrom's ...

A partial hold was placed on the trial after results showed variance between squamous and non-squamous NSCLC patient ...

The RightAI platform aims to assist clinicians in selecting the right patients for clinical trials and make precise treatment ...